ライフサイエンスコーパス: piceatannol

1 ted with the Syk-selective kinase inhibitor, piceatannol.

2 as inhibited by the Syk-selective inhibitor, piceatannol.

3 the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.

4 a rapid accumulation of E-resveratrol and E-piceatannol.

5 he latter was prevented by the Syk inhibitor piceatannol.

6 esults are obtained using the Syk inhibitor, piceatannol.

7 t function caused by kinase-deficient Syk or piceatannol.

8 n be modulated by apigenin, resveratrol, and piceatannol.

9 d ERK1 and ERK2 phosphorylation inhibited by piceatannol.

10 Group 1 (n=8) received piceatannol 30 mg/kg per day intravenously and cyclospor

11 Pharmacologic exposure to piceatannol, a known Syk family kinase inhibitor, inhibi

12 Piceatannol, a natural stilbene, is an analog and a meta

13 Piceatannol, a promising health-promoting stilbene compo

14 Piceatannol, a stilbene analogue to resveratrol with hig

15 with our recent discovery of high amount of piceatannol, a stilbene with potent biological activitie

16 phatidylinositol-3 kinase inhibitor, or with piceatannol, a Syk inhibitor, consistent with uptake thr

17 Pretreatment of PMN with piceatannol, a Syk-selective inhibitor, blocked EIgG pha

18 Pretreatment of PMNs with piceatannol, a Syk-selective inhibitor, blocked Syk acti

19 yrphostin A9, a Pyk2-specific inhibitor, and piceatannol, a Syk-specific inhibitor.

20 yl groups of stilbenes are critical and that piceatannol, a tetrahydroxystilbene, suppresses NF-kappa

21 geting and in human platelets incubated with piceatannol, a tyrosine kinase inhibitor reportedly sele

22 Piceatannol abrogated the expression of TNF-induced NF-k

23 in the natural polymer and demonstrates that piceatannol acts as an authentic monomer participating i

24 Apigenin, resveratrol, and piceatannol all induced Nrf2 translation.

25 Group 3 (n=4) received piceatannol alone as in group 1.

26 Piceatannol also abrogated Ly49A-dependent inhibition of

27 Piceatannol also inhibited NF-kappaB activated by H(2)O(

28 and pharmacological evidence that, although piceatannol also inhibits alphaIIbbeta3 signaling, it do

29 Additionally, piceatannol, an inhibitor of STAT3 activation, down-regu

30 Both piceatannol and a dominant negative behaving Stat3 adeno

31 When Syk phosphorylation was blocked with piceatannol and cells were similarly challenged, phospha

32 induced Syk phosphorylation was inhibited by piceatannol and dominant negative but not wild type Syk

33 study reveals an anti-adipogenic function of piceatannol and highlights IR and its downstream insulin

34 opy of products from the copolymerization of piceatannol and monolignols confirms the structures in t

35 During maturation, the contents in piceatannol and other stilbenes, ellagitannins, and flav

36 we studied the effect of the Syk inhibitors piceatannol and R406 on S1PR1 expression and function.

37 f lignin and implying that compounds such as piceatannol and resveratrol are potentially available in

38 lavonoid derivatives and stilbenes, as trans-piceatannol and resveratrol, as main secondary metabolit

39 ystilbenes, including the valuable compounds piceatannol and resveratrol.

40 rans-stilbene structure of the PTK inhibitor piceatannol and the cis-stilbene structure of the tubuli

41 hesis was detected, whereas with oligomycin, piceatannol, and aurovertin (inhibitors of F(1)F(0)-ATP

42 inase inhibitor genistein, the Syk inhibitor piceatannol, and the RhoA inhibitor C3 exoenzyme had no

43 noncompetitive manner to ATP, through which piceatannol appears to inhibit adipogenesis.

44 n 3-glucoside and the stilbenes resveratrol, piceatannol, astringin and isorhapontin were discovered,

45 models may be due to lack of specificity of piceatannol, because this compound inhibited the activit

46 ere pretreated with the Syk kinase inhibitor Piceatannol before ligation, which abrogated the previou

47 Pretreatment of mDC with the Syk inhibitor piceatannol blocked B7-DC XAb-induced Ag uptake with a c

48 The Syk/Zap inhibitor piceatannol blocked CD28, and TCR induced tyrosine phosp

49 n of Syk function by kinase-deficient Syk or piceatannol blocked target cell-induced PI3K, Rac1, PAK1

50 Piceatannol blocks Syk and ZAP-70, tyrosine kinases invo

51 ation of STAT1 and STAT3 is not inhibited by piceatannol but is sensitive to the Src kinase-specific

52 Whether piceatannol can also suppress NF-kappaB activation was i

53 Piceatannol could be released from these lignins upon de

54 We also showed that piceatannol directly binds to IR and inhibits IR kinase

55 Piceatannol dose-dependently inhibited differentiation m

56 a strong accumulation of E-resveratrol and E-piceatannol during the first six weeks of storage.

57 d gallic acids from pineapple and mango, and piceatannol from passion fruit.

58 , stilbene or rhaponticin (another analog of piceatannol) had no effect, suggesting the critical role

59 s (oligomycin, IC(50) approximately 1.8 muM; piceatannol, IC(50) approximately 1.05 muM; and angiosta

60 Here, we sought to determine the function of piceatannol in adipogenesis and elucidate the underlying

61 n of the development of obesity, the role of piceatannol in the development of adipose tissue and rel

62 tream insulin signaling as novel targets for piceatannol in the early phase of adipogenesis.

63 Piceatannol inhibited NF-kappaB in cells with deleted Sy

64 Both wortmannin and piceatannol inhibited PI 3-kinase, but only piceatannol

65 We found that piceatannol inhibited protein kinase Cdelta (PKCdelta) a

66 The stilbene piceatannol inhibited Syk preferentially over Lyn and ot

67 piceatannol inhibited PI 3-kinase, but only piceatannol inhibited Syk.

68 en examined for the mechanism, we found that piceatannol inhibited TNF-induced IkappaBalpha phosphory

69 We show that piceatannol inhibits adipogenesis of 3T3-L1 preadipocyte

70 Piceatannol is an anti-inflammatory, immunomodulatory, a

71 Moreover, we showed that piceatannol is an inhibitor of IR kinase activity and ph

72 grown sim fruits showed significantly higher piceatannol levels than sun-exposed fruits.

73 of kinase-deficient Syk or pretreatment with piceatannol markedly suppressed IL-2-stimulated activati

74 lue for ATP of 57.8 mum and a K(i) value for piceatannol of 28.9 mum.

75 Inhibition of Syk with piceatannol or PI3K with wortmannin inhibited LPS-induce

76 Piceatannol+oxyresveratrol was tentatively identified in

77 Piceatannol, previously reported as a selective inhibito

78 Piceatannol, previously reported as a Syk/ZAP70-specific

79 We examined whether piceatannol prolongs kidney allograft survival in the st

80 Similarly, the p72(syk) inhibitor piceatannol promoted PMN transmatrix migration, whereas

81 trol, dienestrol, hexestrol, oxyresveratrol, piceatannol, pterostilbene, and resveratrol-3-beta-gluco

82 the spleen tyrosine kinase family inhibitor piceatannol reduced their ability to migrate across the

83 Inhibiting Syk activation with piceatannol results in the inhibition of PIP(3) producti

84 Using a combination of the Syk inhibitor piceatannol, SILAC quantification, peptide fractionation

85 an Syk phosphorylation and is inhibited with piceatannol, suggesting that paxillin is a substrate for

86 The treatment of human myeloid cells with piceatannol suppressed TNF-induced DNA binding activity

87 Furthermore, the piceatannol-suppressed mitotic clonal expansion was acco

88 TNF-induced Syk activation was abolished by piceatannol (Syk-selective inhibitor), which led to the

89 A concentration of piceatannol that inhibited the phosphorylation and kinas

90 o prenylates pinosylvin to chiricanine A and piceatannol to arachidin-5, a prenylated stilbenoid iden

91 Both Syk null murine platelets and piceatannol-treated human platelets exhibited a partial,

92 In the early phase of adipogenesis, piceatannol-treated preadipocytes displayed a delayed ce

93 Down-regulation of Syk by piceatannol treatment impaired NK cellular viability and

94 In contrast, piceatannol treatment of human platelets completely inhi

95 Ultimately, piceatannol was confirmed as a novel inhibitor of ADAMTS

96 This anti-adipogenic property of piceatannol was largely limited to the early event of ad

97 The effect of piceatannol was not restricted to myeloid cells, as TNF-

98 At day 8, piceatannol was reduced to 10 mg/kg per day and the comb

99 These results are the first to show that piceatannol, when combined with subtherapeutic dosages o

100 d with the spleen tyrosine kinase inhibitor, piceatannol, which blocks 'outside-in' beta2 integrin si

101 In contrast to piceatannol, wortmannin did not inhibit PKCdelta and Raf

102 milar requirements and was also sensitive to piceatannol, wortmannin, and LY294002, indicating additi

103 nase) activity and Syk phosphorylation using piceatannol, wortmannin, and LY294002, inhibitors of PI